Oruka Therapeutics, Inc.

ORKA

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0000907654

SEC filings (opens in a new tab)

In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 15 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.

Q3 2024 vs. Q2 2024

How the institutions holding Oruka Therapeutics, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024 All holders in Q2 2024

13F holders of ORKA: Q2 2024 compared with Q3 2024
Measure	Q2 2024	Of which not filed for Q3 2024	Q3 2024	Change
Holders	32	1	42	+11
Shares	12.9M	247.9K	24.6M	+11.9M (+93.8%)
Value	$49.4M	$949.5K	$604.2M	+$555.7M (+1,146.4%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (24)

Institutions that held Oruka Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to ORKA in Q3 2024
Institution	Shares	Value	% of portfolio
FMR LLC	4,682,300	$114.8M	0.01%
Fairmount Funds Management LLC	3,211,922	$78.7M	6.38%
Perceptive Advisors LLC	1,235,187	$30.3M	0.65%
Deep Track Capital, LP	1,235,187	$30.3M	0.97%
Franklin Resources Inc	720,547	$20.0M	0.01%
Paradigm Biocapital Advisors LP	719,660	$17.6M	0.62%
Braidwell LP	515,726	$12.6M	0.36%
Great Point Partners LLC	514,659	$12.6M	3.81%
Point72 Asset Management, L.P.	482,330	$11.8M	0.04%
Frazier Life Sciences Management, L.P.	477,327	$11.7M	0.47%
Redmile Group, LLC	411,728	$10.1M	0.59%
Woodline Partners LP	390,795	$9.58M	0.08%
Sr One Capital Management, LP	375,330	$9.20M	1.84%
Driehaus Capital Management LLC	308,795	$7.57M	0.06%
Price T Rowe Associates Inc	279,648	$6.86M	0.00%
Logos Global Management LP	257,330	$6.31M	0.71%
TD Asset Management Inc	95,076	$2.17M	0.00%
Wellington Management Group LLP	82,137	$2.01M	0.00%
Manufacturers Life Insurance Company, The	42,298	$1.04M	0.00%
Citigroup Inc	26,720	$654.9K	0.00%
Ensign Peak Advisors, Inc	25,000	$612.8K	0.00%
BlackRock, Inc.	21,567	$528.6K	0.00%
New England Capital Financial Advisors LLC	41	$1.00K	0.00%
Danske Bank A/S	2	$49	0.00%

Sold out (13)

Institutions that held Oruka Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of ORKA in Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
Renaissance Technologies LLC	73,099	$280.0K
State Street Corp	59,707	$228.7K
Dimensional Fund Advisors LP	42,502	$162.8K
Standard Life Aberdeen plc	32,461	$124.3K
Cubist Systematic Strategies, LLC	27,779	$106.4K
Northern Trust Corp	20,982	$80.4K
Charles Schwab Investment Management Inc	14,988	$57.4K
Group One Trading, L.P.	7,131	$27.3K
Citadel Advisors LLC	3,985	$15.3K
Simplex Trading, LLC	275	$1.00K
JPMorgan Chase & Co	16	$61
Wells Fargo & Company	0	$1
Royal Bank of Canada	33	$0

Not filed for Q3 2024 yet (1)

Institutions that held Oruka Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ORKA in Q2 2024 that haven't filed for Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
BlackRock Inc.	247,909	$949.5K